Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 12.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 75,452 shares of the biopharmaceutical company’s stock after buying an additional 8,209 shares during the quarter. Envestnet Asset Management Inc. owned about 0.07% of Regeneron Pharmaceuticals worth $79,303,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Global Assets Advisory LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $339,594,000. Capital International Investors raised its position in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the period. First Trust Advisors LP raised its position in shares of Regeneron Pharmaceuticals by 115.2% during the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after purchasing an additional 195,902 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares during the period. Finally, TD Asset Management Inc raised its position in shares of Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock worth $259,402,000 after purchasing an additional 166,998 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on REGN. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Monday. Royal Bank of Canada reissued an “outperform” rating and issued a $1,282.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Argus increased their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Finally, Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,111.30.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,026 shares of company stock worth $11,498,705. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $1,146.75 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20. The stock has a fifty day moving average of $1,128.09 and a 200-day moving average of $1,028.93. The company has a market capitalization of $126.36 billion, a PE ratio of 33.88, a price-to-earnings-growth ratio of 3.97 and a beta of 0.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. As a group, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.